Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1954 1
1964 2
1971 1
1973 1
1974 1
1979 2
1980 1
1983 1
1984 3
1985 3
1988 1
1991 1
1993 1
1994 1
1995 2
1996 3
1997 3
1998 3
1999 4
2000 5
2001 3
2002 3
2003 8
2004 3
2005 3
2006 5
2007 3
2008 3
2009 4
2010 5
2011 19
2012 15
2013 10
2014 6
2015 9
2016 11
2017 13
2018 16
2019 18
2020 16
2021 11
Text availability
Article attribute
Article type
Publication date

Search Results

206 results
Results by year
Filters applied: . Clear all
Page 1
Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study.
Solomon BJ, Besse B, Bauer TM, Felip E, Soo RA, Camidge DR, Chiari R, Bearz A, Lin CC, Gadgeel SM, Riely GJ, Tan EH, Seto T, James LP, Clancy JS, Abbattista A, Martini JF, Chen J, Peltz G, Thurm H, Ou SI, Shaw AT. Solomon BJ, et al. Among authors: james lp. Lancet Oncol. 2018 Dec;19(12):1654-1667. doi: 10.1016/S1470-2045(18)30649-1. Epub 2018 Nov 6. Lancet Oncol. 2018. PMID: 30413378 Clinical Trial.
Lorlatinib in non-small-cell lung cancer with ALK or ROS1 rearrangement: an international, multicentre, open-label, single-arm first-in-man phase 1 trial.
Shaw AT, Felip E, Bauer TM, Besse B, Navarro A, Postel-Vinay S, Gainor JF, Johnson M, Dietrich J, James LP, Clancy JS, Chen J, Martini JF, Abbattista A, Solomon BJ. Shaw AT, et al. Among authors: james lp. Lancet Oncol. 2017 Dec;18(12):1590-1599. doi: 10.1016/S1470-2045(17)30680-0. Epub 2017 Oct 23. Lancet Oncol. 2017. PMID: 29074098 Free PMC article. Clinical Trial.
Resensitization to Crizotinib by the Lorlatinib ALK Resistance Mutation L1198F.
Shaw AT, Friboulet L, Leshchiner I, Gainor JF, Bergqvist S, Brooun A, Burke BJ, Deng YL, Liu W, Dardaei L, Frias RL, Schultz KR, Logan J, James LP, Smeal T, Timofeevski S, Katayama R, Iafrate AJ, Le L, McTigue M, Getz G, Johnson TW, Engelman JA. Shaw AT, et al. Among authors: james lp. N Engl J Med. 2016 Jan 7;374(1):54-61. doi: 10.1056/NEJMoa1508887. Epub 2015 Dec 23. N Engl J Med. 2016. PMID: 26698910 Free PMC article. Clinical Trial.
SIRT1 Controls Acetaminophen Hepatotoxicity by Modulating Inflammation and Oxidative Stress.
Rada P, Pardo V, Mobasher MA, García-Martínez I, Ruiz L, González-Rodríguez Á, Sanchez-Ramos C, Muntané J, Alemany S, James LP, Simpson KJ, Monsalve M, Valdecantos MP, Valverde ÁM. Rada P, et al. Among authors: james lp. Antioxid Redox Signal. 2018 May 1;28(13):1187-1208. doi: 10.1089/ars.2017.7373. Epub 2017 Dec 11. Antioxid Redox Signal. 2018. PMID: 29084443
Acetaminophen-induced hepatotoxicity.
James LP, Mayeux PR, Hinson JA. James LP, et al. Drug Metab Dispos. 2003 Dec;31(12):1499-506. doi: 10.1124/dmd.31.12.1499. Drug Metab Dispos. 2003. PMID: 14625346 Review.
Translational biomarkers of acetaminophen-induced acute liver injury.
Beger RD, Bhattacharyya S, Yang X, Gill PS, Schnackenberg LK, Sun J, James LP. Beger RD, et al. Among authors: james lp. Arch Toxicol. 2015 Sep;89(9):1497-522. doi: 10.1007/s00204-015-1519-4. Epub 2015 May 17. Arch Toxicol. 2015. PMID: 25983262 Free PMC article. Review.
206 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page